Terren Peizer - Biovie CEO, Director
| BIVI Stock | USD 0.49 0.01 2.08% |
CEO
Mr. Terren S. Peizer is Chief Executive Officer, Director of the company. He has served as the Chief Executive Officer and Chairman of the Board of Directors of Catasys, Inc., a healthcare company, since 2003. Mr. Peizer is also the founder, Chairman and CEO NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neurodegenerative diseases. In addition to his roles with Catasys and NeurMedix, Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal investment vehicle, and holding company that is the owner of all of his portfolio company interests. Through Acuitas, Mr. Peizer owns Acuitas Capital, LLC, an industry leader in investing in micro and small capitalization equities, having invested over 1.5 billion directly into portfolio companies. Mr. Peizer was the largest beneficial shareholder of, and has held various senior executive positions with, several other publiclytraded growth companies, including having served as Chairman of Cray, Inc. a supercomputer company. Mr. Peizer has a background in VC, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. The Company believes that Mr. Peizers extensive knowledge and experience in the financial and healthcare industries, and his extensive insight and experience with capital markets and publicly traded companies at all stages of development, qualifies him to serve as our CEO and on our board of directors since 2018.
| Age | 57 |
| Tenure | 6 years |
| Address | 680 West Nye Lane, Carson City, NV, United States, 89703 |
| Phone | 775 888 3162 |
| Web | https://bioviepharma.com |
Terren Peizer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Terren Peizer against Biovie stock is an integral part of due diligence when investing in Biovie. Terren Peizer insider activity provides valuable insight into whether Biovie is net buyers or sellers over its current business cycle. Note, Biovie insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biovie'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Terren Peizer over a week ago Disposition of 36666666 shares by Terren Peizer of Ontrak at 0.85 subject to Rule 16b-3 | ||
Terren Peizer over two weeks ago Acquisition by Terren Peizer of 90548129 shares of Ontrak at 0.3442 subject to Rule 16b-3 |
Biovie Management Efficiency
The company has return on total asset (ROA) of (0.8082) % which means that it has lost $0.8082 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5784) %, meaning that it created substantial loss on money invested by shareholders. Biovie's management efficiency ratios could be used to measure how well Biovie manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.39. The current Return On Capital Employed is estimated to decrease to -2.64. As of now, Biovie's Non Current Assets Total are increasing as compared to previous years. The Biovie's current Other Assets is estimated to increase to 5,509, while Non Currrent Assets Other are projected to decrease to 0.00.Similar Executives
| Found 5 records | CEO Age | ||
| Daniel MBA | Acumen Pharmaceuticals | 53 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
Management Performance
| Return On Equity | -2.58 | ||||
| Return On Asset | -0.81 |
Biovie Inc Leadership Team
Elected by the shareholders, the Biovie's board of directors comprises two types of representatives: Biovie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biovie. The board's role is to monitor Biovie's management team and ensure that shareholders' interests are well served. Biovie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biovie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mina Sooch, Independent Director | ||
| Joseph MD, Executive Officer | ||
| Richard Berman, Director | ||
| Jonathan Adams, President COO, Director | ||
| Wendy Kim, CFO, Corporate Secretary | ||
| Joanne CPA, Treasurer CFO | ||
| James Lang, Independent Director | ||
| Michael Sherman, Independent Director | ||
| Patrick Yeramian, Chief Medical Officer | ||
| Penelope Markham, Chief Scientific Officer | ||
| Christopher Reading, Senior Program | ||
| Terren Peizer, CEO, Director | ||
| Cuong MBA, CEO President | ||
| Richard Wieland, Interim CFO | ||
| Elliot Ehrlich, Chairman of the Board, CEO, CFO, Treasurer, Corporate Secretary | ||
| Clarence Ahlem, Senior Operations | ||
| Denise Smith, Senior Development | ||
| Hari Kumar, Independent Director | ||
| Julie Anderson, Independent Director | ||
| Sarah Hoit, Chief Officer | ||
| Rajah Menon, President Director | ||
| MBA MBA, CEO Pres |
Biovie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biovie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.58 | ||||
| Return On Asset | -0.81 | ||||
| Current Valuation | 9.42 M | ||||
| Shares Outstanding | 54.92 M | ||||
| Shares Owned By Insiders | 43.25 % | ||||
| Shares Owned By Institutions | 4.40 % | ||||
| Number Of Shares Shorted | 1.48 M | ||||
| Price To Earning | 18.12 X | ||||
| Price To Book | 3.80 X | ||||
| EBITDA | (44.29 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biovie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biovie's short interest history, or implied volatility extrapolated from Biovie options trading.
Pair Trading with Biovie
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biovie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biovie will appreciate offsetting losses from the drop in the long position's value.Moving together with Biovie Stock
| 0.64 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Biovie Stock
| 0.69 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.68 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.62 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.6 | OPT | Opthea | PairCorr |
| 0.44 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Biovie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biovie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biovie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biovie Inc to buy it.
The correlation of Biovie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biovie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biovie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biovie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biovie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Biovie Stock analysis
When running Biovie's price analysis, check to measure Biovie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovie is operating at the current time. Most of Biovie's value examination focuses on studying past and present price action to predict the probability of Biovie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovie's price. Additionally, you may evaluate how the addition of Biovie to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Biovie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biovie. If investors know Biovie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biovie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.81) | Return On Equity (2.58) |
The market value of Biovie Inc is measured differently than its book value, which is the value of Biovie that is recorded on the company's balance sheet. Investors also form their own opinion of Biovie's value that differs from its market value or its book value, called intrinsic value, which is Biovie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biovie's market value can be influenced by many factors that don't directly affect Biovie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biovie's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biovie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biovie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.